靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用

国际肿瘤学杂志››2023,Vol. 50››Issue (10): 631-635.doi:10.3760/cma.j.cn371439-20230428-00120

靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用

于晓鹏¹, 冯青青², 赵文飞², 赵文文², 魏红梅²()

¹潍坊医学院临床医学院，潍坊 261053
²青岛大学附属青岛市中心医院肿瘤综合二科，青岛 266042

收稿日期:2023-04-28修回日期:2023-08-01出版日期:2023-10-08发布日期:2023-11-08
通讯作者:魏红梅 E-mail:13001776675@163.com
基金资助:
青岛市医药卫生科研计划(2021-WJZD081)

Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer

Yu Xiaopeng¹, Feng Qingqing², Zhao Wenfei², Zhao Wenwen², Wei Hongmei²()

¹School of Clinical Medicine， Weifang Medical University， Weifang 261053， China
²Second Department of General Oncology， Affiliated Qingdao Central Hospital， Qingdao University， Qingdao 266042， China

Received:2023-04-28Revised:2023-08-01Online:2023-10-08Published:2023-11-08
Contact:Wei Hongmei E-mail:13001776675@163.com
Supported by:
Qingdao Medical and Health Research Project(2021-WJZD081)

摘要/Abstract

摘要：

人表皮生长因子受体2（HER2）、程序性死亡受体1、程序性死亡受体配体1与多种肿瘤细胞的增殖、侵袭和转移相关，靶向HER2的多种抗体及小分子药物已在临床取得可观的结果，针对程序性死亡受体1、程序性死亡受体配体1的免疫检查点抑制剂在临床应用中效果显著。在KEYNOTE-811试验中，免疫检查点抑制剂与靶向治疗的联合应用在HER2阳性进展期胃癌中取得了令人振奋的结果。

关键词:胃肿瘤,受体，erbB-2,免疫检查点抑制剂

Abstract:

Human epidermal growth factor receptor 2 （HER2）， programmed death-1 and programmed death-ligand 1 are related to the proliferation， invasion and metastasis of various tumor cells. A variety of antibodies and small molecule drugs targeting HER2 have achieved considerable results in clinical practice. Immune checkpoint inhibitors targeting programmed death-1 and programmed death-ligand 1 have significant effects in clinical application. In the KEYNOTE-811 trial， the combination of immune checkpoint inhibitors and targeted therapy has achieved encouraging results in HER2-positive advanced gastric cancer.

Key words:Stomach neoplasms,Receptor， erbB-2,Immune checkpoint inhibitors

于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.

Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.

参考文献29

[1]	中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)胃癌诊疗指南2022[M]. 北京: 人民卫生出版社,2022.
[2]	Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion[J].Cancer Lett,2018,430: 47-56. DOI:10.1016/j.canlet.2018.05.009. pmid:29746929
[3]	Voutsadakis IA. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer[J].Clin Transl Oncol,2019,21(5): 539-555. DOI:10.1007/s12094-018-1961-x. pmid:30306401
[4]	Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer[J].Br J Cancer,2021,124(3): 595-603. DOI:10.1038/s41416-020-01138-3.
[5]	Iwata TN, Ishii C, Ishida S, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model[J].Mol Cancer Ther,2018,17(7): 1494-1503. DOI:10.1158/1535-7163.MCT-17-0749. pmid:29703841
[6]	Mandikian D, Takahashi N, Lo AA, et al. Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model[J].Mol Cancer Ther,2018,17(4): 776-785. DOI:10.1158/1535-7163.MCT-17-0657. pmid:29339550
[7]	Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J].Nature,2021,600(7890): 727-730. DOI:10.1038/s41586-021-04161-3.
[8]	Subramanian J, Katta A, Masood A, et al. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers[J].Oncologist,2019,24(12): e1303-e1314. DOI:10.1634/theoncologist.2018-0845.
[9]	Patsoukis N, Wang Q, Strauss L, et al. Revisiting the PD-1 pathway[J].Sci Adv,2020,6(38): eabd2712. DOI:10.1126/sciadv.abd2712.
[10]	Böger C, Behrens HM, Mathiak M, et al. PD-L1 is an independent prognostic predictor in gastric cancer of western patients[J].Oncotarget,2016,7(17): 24269-24283. DOI:10.18632/oncotarget.8169. pmid:27009855
[11]	赵丽丽, 赵文文, 冯青青, 等. 沉默PD-L1表达对胃癌细胞生物学行为的影响[J].国际肿瘤学杂志,2021,48(12): 705-710. DOI:10.3760/cma.j.cn371439-20210813-00140.
[12]	Wang L, Zhang Q, Ni S, et al. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status[J].Cancer Med,2018,7(6): 2612-2620. DOI:10.1002/cam4.1502.
[13]	Lian J, Zhang G, Zhang Y, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance[J].Dig Liver Dis,2022,54(10): 1419-1427. DOI:10.1016/j.dld.2022.01.128.
[14]	Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol, 2018, 4(5): e180013.DOI:10.1001/jamaoncol.2018.0013.
[15]	Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J].Lancet,2018,392(10142): 123-133. DOI:10.1016/S0140-6736(18)31257-1. pmid:29880231
[16]	Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10): 1571-1580. DOI:10.1001/jamaoncol.2020.3370.
[17]	Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J].Lancet Oncol,2019,20(3): 371-382. DOI:10.1016/S1470-2045(18)30812-X. pmid:30765258
[18]	Rha SY, Lee CK, Kim HS, et al. Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ⅰb/Ⅱ trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC)[J].J Clin Oncol,2020,38(38(15_suppl): 3081. DOI:10.1200/JCO.2020.
[19]	Lee CK, Rha SY, Kim HS, et al. A single arm phase Ⅰb/Ⅱ trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer[J].Nat Commun,2022,13(1): 6002. DOI:10.1038/s41467-022-33267-z.
[20]	Wang KX, Cui TY, Yang XD, et al. Study on efficacy and safety of low-dose apatinib combined with camrelizumab and SOX regimen as first-line treatment of locally advanced and unresectable gastric/gastroesophageal junction cancer: a protocol for an open-label, dose escalation and extension phaseⅠb clinical trial[J].Onco Targets Ther,2021,14: 4859-4865. DOI:10.2147/OTT.S316288.
[21]	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer (version 1.2023)[EB/OL]. [2023-04-10]. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
[22]	Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J].Cancer,2019,125(5): 742-749. DOI:10.1002/cncr.31855. pmid:30508306
[23]	Xu M, Meng X, Lu Y, et al. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer[J].J Gastrointest Oncol,2022,13(2): 548-558. DOI:10.21037/jgo-21-897. pmid:35557572
[24]	张鑫鑫, 李帅, 吴晨, 等. HER-2阳性晚期胃癌免疫治疗临床分析[J].中国肿瘤临床,2022,49(16): 840-845. DOI:10.12354/j.issn.1000-8179.2022.20220156.
[25]	Markham A. Margetuximab: first approval[J].Drugs,2021,81(5): 599-604. DOI:10.1007/s40265-021-01485-2. pmid:33761116
[26]	Catenacci DVT, Kang YK, Park H, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial[J].Lancet Oncol,2020, 21(8): 1066-1076. DOI:10.1016/S1470-2045(20)30326-0.
[27]	Stein A, Paschold L, Tintelnot J, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial[J].JAMA Oncol,2022,8(8): 1150-1158. DOI:10.1001/jamaoncol.2022.2228. pmid:35737383
[28]	Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2⁺unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma[J].Future Oncol,2021,17(10): 1155-1164. DOI:10.2217/fon-2020-1007. pmid:33263418
[29]	Catenacci DVT, Kang YK, Yoon HH, et al. Margetuximab with retifanlimab as first-line therapy in HER2⁺/PD-L1⁺unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A[J].ESMO Open,2022,7(5): 100563. DOI:10.1016/j.esmoop.2022.100563.